# A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

> **NCT04613518** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 38 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** BMS-986165
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT04613518
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-11-29
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04613518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04613518, "A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04613518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*